High Response Rates in Psoriasis With Oral IL-23 Inhibitor
An oral interleukin (IL)-23 inhibitor for psoriasis produced 16-week response rates as high as 79% in moderate-to-severe plaque psoriasis, a prospective phase II trial showed. The drug (JNJ-77242113) achieved response rates of 37% to 79% across five dose levels. In contrast, patients treated with placebo had a 9% response rate at 16 weeks. The most […]
Durable Responses, Safety in Atopic Dermatitis Treated With IL-13 Inhibitor
The interleukin (IL)-13 inhibitor tralokinumab (Adbry) for atopic dermatitis provided long-term disease control with a favorable safety profile and improved quality of life (QoL), data from two studies showed. Interim results from a long-term extension study showed that 82.5% of patients had at least 75% improvement in the Eczema Area and Severity Index (EASI-75) after […]